Research Reports

Pharmeasy Unlisted Shares

Pharmeasy company logo

Pharmeasy Share Price

PHYSICAL

PUBLIC LIMITED

Price Chart

1W
1M
1Y
MAX

High

₹51

Low

₹5.24

Return

-15.48%

Buy Sell Pharmeasy Unlisted Shares

As of May 18, 2026, API Holdings (Pharmeasy), Unlisted Shares are trading at ₹5.28 per share and face value is ₹1.00/share, with a 52-week high of ₹7.00 and 52-week low of ₹5.00. The minimun lot size is 9000 shares, and the shares are traded on NSDL and CDSL.

ISIN

info icon

INE0DJ201029

Face Value

info icon

1

Total Shares

info icon

6,51,66,68,712

Market Cap

info icon

3,440.8 Cr

Profit After Tax

info icon

-1,572.39 Cr

Total Revenue

info icon

5,898.46 Cr

P/E

info icon

-2.19

P/B

info icon

1.17

Sector

info icon

Health Care

Sub-sector

info icon

Pharmaceuticals

Category

info icon

Micro Cap

Cashflow - Operations

info icon

-223.53 Cr

About Pharmeasy

PharmEasy, operated under API Holdings Limited, is one of India’s leading integrated digital healthcare platforms, offering end-to-end healthcare solutions across e-pharmacy, diagnostics, teleconsultation, and healthcare software. Founded in 2015 by Siddharth Shah, Hardik Dedhia, and Harsh Parekh, the company aims to improve access to affordable and reliable healthcare across India.

Through its consumer-facing PharmEasy app, the company enables on-demand home delivery of prescription medicines, over-the-counter healthcare products, nutraceuticals, and wellness essentials. PharmEasy has also built a strong diagnostics presence, providing home sample collection and diagnostic testing services across major Indian cities. These diversified healthcare verticals have made PharmEasy shares a closely tracked asset in the Indian unlisted market.

API Holdings ecosystem extends beyond consumer healthcare. Its subsidiaries include Retailio, a B2B pharmaceutical distribution platform serving pharmacies and hospitals, and Redbook, an enterprise resource planning (ERP) and pharmacy CRM solution that helps retail pharmacies manage inventory, billing, and operations. The group also offers teleconsultation and allied healthcare services, creating a vertically integrated healthcare delivery model that supports long-term scalability and revenue diversification.

In 2021, the company strengthened its diagnostics portfolio by acquiring a 66% stake in Thyrocare Technologies, becoming one of the first Indian unicorns to acquire a listed company. API Holdings has also launched PharmEasy SurgiCare, focusing on elective surgeries across key urban centers such as Mumbai, Delhi, Bengaluru, Chennai, Pune, and Indore.

API Holdings serves a wide network of pharmacies, hospitals, clinics, and healthcare providers across India, supported by a workforce of over 4,000 employees and an extensive partner pharmacy network. In recent developments, PharmEasy share price in the unlisted market has reflected ongoing capital restructuring efforts, including the company’s plan to raise approximately ₹2,400 crore through a rights issue, aimed at strengthening its balance sheet and meeting debt obligations.

Want to See a Detailed Investment Analysis?

Explore in-depth financial analysis, performance metrics, and key disclosures.

Pharmeasy Media

News

Articles

Videos

PharmEasy Parent API Holdings Raises ₹1,700 Crore, Pledges 61% Stake in Thyrocare as Collateral

PharmEasy Parent API Holdings Raises ₹1,700 Crore, Pledges 61% Stake in Thyrocare as Collateral

24 Sep 2025

Angel One

PharmEasy re-enters TV with diagnostics campaign

PharmEasy re-enters TV with diagnostics campaign

04 May 2025

Afaqs

PharmEasy sets stage for IPO return with new strategy, boosted cash flow

PharmEasy sets stage for IPO return with new strategy, boosted cash flow

20 Jan 2025

Business Standard

Frequently Asked Question (FAQs)

Where can I find the annual report of API Holdings (Pharmeasy) Ltd?

The annual report of API Holdings (Pharmeasy) Ltd is available in the annual report section.

How to buy API Holdings (Pharmeasy) Unlisted Shares?

Please find below the procedure for buying API Holdings (Pharmeasy) Unlisted Shares at Planify.
• 1. You confirm booking of API Holdings (Pharmeasy) Unlisted Shares with us at a trading price.
• 2. You provide your client master report (ask the broker if not available) along with PAN Card and Cancelled Cheque in case you are not transferring funds from the bank account as mentioned in the CMR Copy. These are KYC documents required as per SEBI regulations.
• 3. We will provide the bank details.
• 4. You need to transfer funds in that account.
• 5. Payment has to be done in RTGS/NEFT/IMPS CHEQUE TRANSFER. No CASH DEPOSIT.
• 6. Payment has to be done from the same account in which shares are to be credited.
• 7. We will transfer the shares in 24 hours if funds are credited before 2 pm.
Important Note: Please note that the lock-in period for selling API Holdings (Pharmeasy) Unlisted Shares is 6 months after listing. Hence you can’t sell API Holdings (Pharmeasy) Unlisted Shares which you bought in Pre-IPO for 6 months after its listing. i.e. You can sell it only after 6 months calculated from the listing date.

What is the lock-in period of API Holdings (Pharmeasy) Unlisted Shares?

Lock-in period of API Holdings (Pharmeasy) Unlisted Shares depends upon category of investors.
• 1. Venture Capital Funds or Alternate Investment Fund of Category -I or II, or Foreign Venture Capital Investor - lock-in Period of 6 months from the date of acquisition of API Holdings (Pharmeasy) Unlisted Shares.
• 2. Other Investors (include Retail, HNIs or Body Corporate) lock-in Period of 6 months from the date of listing of IPO of API Holdings (Pharmeasy) Unlisted Shares.
This new SEBI rule was introduced in the month of August-2021, wherein the SEBI has reduced the lock-in period previously from 1 year to 6 months to encourage more and more funds to be invested in startups which are going to public or IPO in near future. Reduction of lock-in is seen as big step and after that many PMS funds are advising their clients to invest in Pre-IPO shares to get the benefit of early stage investment.

See More

Pharmeasy

₹ 5.28

cartIcon